MED15 and neoplasm: Concerning renal cell carcinoma, preclinical models have shown that HIF2α-dependent MED15 over-expression may promote lipid deposition and tumor progression through sterol regulatory element binding protein (SREBP) coactivation via the AKT pathway [26].